Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC) in inflammatory bowel disease (IBD) at the 19th ECCO Congress
Health Canada Approves Remsima™ SC for the Treatment of IBD
JERSEY CITY, N.J., Jan. 28, 2024 /PRNewswire/ -- Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar candidate of the reference product ACTEMRA® (tocilizumab)[1].
Shortly after its spinoff and IPO, WuXi Biologics’ subsidiary WuXi XDC has locked up a major customer on its quest to establish itself as a premier bioconjugation contract research, development and manufacturing organization.
Celltrion`s Biologic Yuflyma (adalimumab) Receives Approval in the U.S.
Celltrion USA announces distribution and incorporation of YUFLYMA
Celltrion, Inc. & Celltrion Healthcare Co., Ltd. Announce Shareholders Approval of Merger
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
Celltrion`s Biologic Zymfentra (infliximab) Receives Approval in the U.S.